Le Lézard
Classified in: Health
Subject: SVY

Increased use of higher-cost medicines continues to put pressure on Canadian public drug plans


OTTAWA, ON, Jan. 31, 2023 /CNW/ - A new Patented Medicine Prices Review Board (PMPRB) report finds that prescription drug expenditures by Canadian public drug plans increased by 4.2% in 2020-21, bringing annual spending to $12.3 billion. The use of higher-cost medicines has been the primary factor behind rising costs for the public plans over the past five years, and this pressure continues to build.

In 2020-21, high-cost drugs accounted for over one third of total drug costs and yet were only used by 2.5% of drug plan beneficiaries. The 10 highest-cost drugs reimbursed by the public drug plans were all rare disease treatments with annual treatment costs of over $200,000.

These findings were released today by the PMPRB in the eighth edition of CompassRx, an annual report published under the National Prescription Drug Utilization Information System (NPDUIS) research initiative. CompassRx provides insight into the factors driving prescription drug expenditures in select Canadian public drug plans. This edition focuses on the 2020-21 fiscal year.

The study includes all provincial public drug plans (with the exception of Quebec), as well as Yukon and the Non-Insured Health Benefits Program. These plans account for approximately one third of the total annual spending on prescription drugs in Canada.

Quick Facts
Associated Links

CompassRx, 8th edition: Annual Public Drug Plan Expenditure Report, 2020/21

Follow us on Twitter: @PMPRB_CEPMB

SOURCE Patented Medicine Prices Review Board


These press releases may also interest you

at 06:45
The "Global Pediatric Interventional Cardiology Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to  ResearchAndMarkets.com's offering. The Global Pediatric...

at 06:30
The "Sample Preparation Market by Product (Workstation, Instrument {Pipette, Washer, Centrifuge, Grinder}, Consumable {Kits, Filters, Plates}) Technique (Solid Phase Extraction, Purification) Application (Drug Discovery, Diagnostic) - Global Forecast...

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 06:08
ConTemporary Locums, a physician-focused medical staffing company, is ushering in a new era with a bold rebrand: Era Locums. This brand evolution marks a commitment to continued innovation and a deeper connection with the company's physician and...

at 06:05
AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March 25-31 as National Physicians Week. This week and throughout the year, we celebrate the dedication of physicians who selflessly...

at 06:00
The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to  ResearchAndMarkets.com's...



News published on and distributed by: